Adenoviral down-regulation of osteopontin inhibits human osteoclast differentiation in vitro

Journal of Cellular Biochemistry
Cathy J AitkenGeoffrey C Nicholson

Abstract

Although osteopontin (OPN) is highly expressed in osteoclasts, OPN-deficient mice have a near-normal bone phenotype and its role in osteoclast differentiation and function remains uncertain. We used an adenoviral OPN-antisense vector (AdOPN-AS) to down-regulate OPN expression in a human in vitro osteoclastogenesis model employing CFU-GM precursors treated with RANKL and M-CSF. Cultures infected with AdOPN-AS showed reduced secretion of OPN compared to cultures infected with a control adenoviral vector expressing beta-galactosidase. Infection with AdOPN-AS co-incident with exposure to RANKL was associated with substantial (approximately 50%) inhibition of osteoclast formation with a concomitant reduction in dentine resorption. There was also a small reduction in the size of generated osteoclasts but no significant effect on the size of resorption pits/tracks nor on the amount of resorption per osteoclast. When the cultures were infected with AdOPN-AS after 4 days exposure to RANKL only minor effects on osteoclastogenesis were seen. Our data demonstrate that early down-regulation of OPN in vitro inhibits human osteoclastogenesis. Since mice totally lacking OPN do not have reduced osteoclast numbers our results imply the existence...Continue Reading

References

Jul 31, 1992·Biochemical and Biophysical Research Communications·K TezukaM Kumegawa
Aug 1, 1992·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·T IkedaS Yoshiki
Jun 28, 1991·Biochemical and Biophysical Research Communications·C W PrinceC L Krumdieck
Jun 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·F P ReinholtD Heinegård
Dec 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·A OldbergD Heinegård
Aug 1, 1997·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·J R KaniaS R Kupfer
Aug 1, 1997·Journal of Periodontal Research·N Tani-IshiiT Umemoto
Apr 29, 1998·The Journal of Clinical Investigation·L LiawB L Hogan
Jul 14, 1998·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·S R RittlingD T Denhardt
Nov 3, 1998·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·S TanakaT Kurokawa
Jul 8, 1999·Proceedings of the National Academy of Sciences of the United States of America·H YoshitakeM Noda
Dec 5, 2000·The Journal of Biological Chemistry·L T DuongG A Rodan
Mar 30, 2001·The Journal of Biological Chemistry·H IharaM Noda
Dec 7, 2002·Calcified Tissue International·M A Chellaiah, K A Hruska
Jan 17, 2003·Molecular Biology of the Cell·M A ChellaiahK A Hruska
Feb 19, 2004·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Jason M HodgeGeoffrey C Nicholson

❮ Previous
Next ❯

Citations

May 29, 2007·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Anna KiialainenLeena Peltonen
May 17, 2008·Journal of Materials Science. Materials in Medicine·Rupak M RajacharCecilia M Giachelli
Sep 17, 2005·American Journal of Respiratory and Critical Care Medicine·Prescott G WoodruffDavid J Erle
Jan 27, 2006·The American Journal of Pathology·Tajneen NatashaSusan R Rittling
Oct 29, 2011·Cell Biology International·Hong GaoKenneth S Ramos
Jul 20, 2007·Journal of Biomedical Materials Research. Part a·Maria KarpovAnna M Osyczka
Sep 29, 2006·American Journal of Physiology. Cell Physiology·Asad JunaidPeter Zahradka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.